PeptideDB

Noraramtide

CAS: 2580150-96-3 F: C210H300N48O65S3 W: 4633.11

Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recru
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity[1].
CAS 2580150-96-3
Sequence Ala-Arg-{2-aminoheptanoicacid}-Tyr-His-Asp-Gly-Val-Leu-{Phe(4-phenyl)}-{2-aminoheptanoicacid}-{d-Cys(s-carboxymethyl)}-{XGly}-{γGlu}-{γGlu}-{d-γGlu}-{γGlu}-{γGlu}-Gly-Gly-Asp-Cys-Ala-Trp-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (Sulfidebridge:Ala1-Cys13,Disulfidebridge:Cys24-Cys34) X= NH2-PEG6-((6S)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methyl hydrogen carbonate-piperidine-4-carboxylic acid
Shortening AR-{2-aminoheptanoicacid}-YHDGVL-{Phe(4-phenyl)}-{2-aminoheptanoicacid}-{d-Cys(s-carboxymethyl)}-{XGly}-{γGlu}-{γGlu}-{d-γGlu}-{γGlu}-{γGlu}-GGDCAWHLGELVWCT (Sulfidebridge: Ala1-Cys13,Disulfidebridge:Cys24-Cys34) X= NH2-PEG6-((6S)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methyl hydrogen carbonate-piperidine-4-carboxylic acid
Formula C210H300N48O65S3
Molar Mass 4633.11
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Birch G C, et al. Expansion, persistence, and characteristics of autologous, Bhv-1100 armored memory-like NK cells infused prior to autologous stem cell transplant in MRD+ multiple myeloma patients: a first-in-human trial[J]. Blood, 2023, 142: 2105.